Hypomethylation of CTCFL promoters as a noninvasive biomarker in plasma from patients with hepatocellular carcinoma

Rok, strany: 2020, 909 - 915

Hepatocellular carcinoma (HCC) is the third deadliest cancer in the world with high morbidity and poor prognosis. CTCFL (CCCTC-binding factor like) is a member of the cancer testis antigen (CTA) family with oncogenic properties. To demonstrate whether the hypomethylation of CTCFL promoters in plasma could be used as a noninvasive biomarker to predict poor prognosis of HCC, we extracted cell-free DNA from the plasma and detected the methylation status of CTCFL in 43 HCC, 5 liver cirrhosis and 6 benign lesion samples using methylation specific PCR (MSP). Our study indicated that the hypomethylation of CTCFL promoters in HCC plasma samples (60.4%) was significantly different from that in benign lesion plasma samples (16.7%) with a p-value of 0.043. Analysis of clinicopathological data showed that the methylation status of CTCFL promoters was significantly correlated with microvascular involvement (MVI) (p=0.001) and postoperative recurrence (p=0.031). Furthermore, clinical prognosis data of 347 HCC patients from The Cancer Genome Atlas (TCGA) database displayed that the hypomethylated group had worse overall survival than the hypermethylated group (p=0.0056). In conclusion, we provide evidence that the hypomethylation of CTCFL promoters in cell-free DNA is a biomarker for monitoring HCC patients, which can be used as a noninvasive prediction index for tumor recurrence and provide the individualized decision-making for clinicians.

ISO 690:

Chen, M., Zhao, R., Chen, K., Huang, Y., Liu, Z., Wei, Y., Jian, Y., Sun, A., Qin, L., Li, B., Qin, Y. 2020. Hypomethylation of CTCFL promoters as a noninvasive biomarker in plasma from patients with hepatocellular carcinoma. In NEOPLASMA, vol. 67, no.4, pp. 909-915. 0028-2685. DOI: https://doi.org/10.4149/neo_2020_190819N789

APA:

Chen, M., Zhao, R., Chen, K., Huang, Y., Liu, Z., Wei, Y., Jian, Y., Sun, A., Qin, L., Li, B., Qin, Y. (2020). Hypomethylation of CTCFL promoters as a noninvasive biomarker in plasma from patients with hepatocellular carcinoma. NEOPLASMA, 67(4), 909-915. 0028-2685. DOI: https://doi.org/10.4149/neo_2020_190819N789

Vydavateľ: AEPress, Ltd.